Aripiprazole Tablet
Product Images NDC 68788-7749

11 FDA label images from Preferred Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Struct)

Structure (Aripiprazole Struct)
Chemical structure of aripiprazole, showing its molecular framework with chlorine atoms, piperazine ring, and quinolinone moiety as depicted in the image.*
FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

Aripiprazole_fig_01 (Aripiprazole Fig 01)
A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax. The chart compares changes relative to a reference without interacting drugs, listing drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*
FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

Aripiprazole_fig_02 (Aripiprazole Fig 02)
A scatter plot showing the effect of various drugs on the pharmacokinetics of Aripiprazole. The graph plots fold change and 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs, listing inhibitors, inducers, and other drugs against Aripiprazole exposure.*
FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

Aripiprazole_fig_03 (Aripiprazole Fig 03)
A forest plot titled 'Effect of Aripiprazole on other Drugs' showing fold change and 90% confidence intervals for the pharmacokinetics (PK) of various drugs including CYP2D6 and CYP2C9 substrates, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis depicts change relative to reference (without interacting drug) ranging from 0.0 to 3.0, with plotted points mostly clustered near 1.0 indicating minimal fold change.*
FDA Label Image

Figure4 (Aripiprazole Fig4)

Figure4 (Aripiprazole Fig4)
A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes relative to reference across special populations. It compares AUC and Cmax for groups including CYP2D6 poor vs. extensive metabolizers, female vs. male, age groups, and various degrees of hepatic and renal impairment, illustrating the fold change with 90% confidence intervals.*
FDA Label Image

Figure5 (Aripiprazole Fig5)

Figure5 (Aripiprazole Fig5)
A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying fold change in AUC and Cmax relative to reference, comparing effects of CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment on drug levels.*
FDA Label Image

Figure6 (Aripiprazole Figure6)

Figure6 (Aripiprazole Figure6)
A line graph showing the proportion of relapse over days from randomization, comparing Aripiprazole and Placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse. Two curves illustrate relapse rates for Aripiprazole and Placebo, with numbers of subjects at risk listed below the x-axis at various time points.*
FDA Label Image

Figure7 (Aripiprazole Figure7)

Figure7 (Aripiprazole Figure7)
A line graph comparing the proportion of relapse over 182 days from randomization between Aripiprazole and placebo groups. The graph shows the number of subjects at risk at various time points and illustrates relapse trends for both treatments in a clinical study context.*
FDA Label Image

Figure8 (Aripiprazole Figure8)

Figure8 (Aripiprazole Figure8)
A line graph comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization (0 to 364) and the number of subjects at risk at various time points. The y-axis represents the proportion with relapse, ranging from 0.0 to 1.0. The Aripiprazole group shows a consistently lower relapse proportion than the placebo group.*
FDA Label Image

Figure9 (Aripiprazole Fig9)

Figure9 (Aripiprazole  Fig9)
A line graph showing the least-squares mean change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, with tic scores decreasing over time for both Aripiprazole groups more than placebo.*
FDA Label Image

Aripiprazole Tablets Usp 5mg (Aripiprazole 5mg)

Aripiprazole Tablets Usp 5mg (Aripiprazole 5mg)
Label for Aripiprazole Tablets, USP 5 mg, a human prescription oral tablet by Preferred Pharmaceuticals, Inc. The label states the product is generic for Abilify and includes storage instructions, caution about federal law, and dosage directions in English and Spanish. The tablet is described as round, yellow, and imprinted with AZ / 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.